Nuevolution AB (publ) announces milestone payment from big pharma collaboration

Stockholm, 22 February 2016, Nuevolution AB (publ) announces that it will
receive a milestone payment of USD 2 million from its drug discovery
collaboration with Novartis.
Nuevolution AB (publ) announces milestone payment from big pharma collaboration

Stockholm, 22 February 2016, Nuevolution AB (publ) announces that it will
receive a milestone payment of USD 2 million from its drug discovery
collaboration with Novartis.

In August 2009, Nuevolution and Novartis entered into a collaboration to apply
Nuevolution’s proprietary Chemetics® drug discovery technology to identify novel
small molecule leads against drug targets of interest to Novartis. In 2014 the
companies signed a non-exclusive technology licensing agreement to enable
Novartis to use this technology internally and to co-produce novel screening
libraries with Nuevolution. To date Nuevolution has received an upfront payment,
research funding and milestone payments.

“It remains part of our strategy to boost the use of our Chemetics® drug
discovery platform in both our internal programs as well as through the
application of our discovery platform in strategic partnerships and product
licensing arrangements. The collaboration with Novartis supports the
attractiveness of our proprietary Chemetics® platform, in the search for the
attractive drug candidates addressing major unmet medical needs“, said Alex
Gouliaev, CEO of Nuevolution AB (publ).

For more information, please contact:
Alex Haahr Gouliaev, CEO
Phone: +45 70 20 09 87
Email: AHG@nuevolution.com


About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company
founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its
proprietary discovery platform and programs with pharmaceutical and
biotechnology companies to seek future benefit of patients in need of novel
medical treatment options. Nuevolution’s internal programs are focused on
therapeutically important targets within inflammation, oncology and immuno
-oncology.

Nuevolution AB (publ) is required to disclose the information provided herein
pursuant to the Securities Markets Act and/or the Financial Instruments Trading
Act. The information was sent for publication on Monday 22 February 2016, 09.00
(CET).

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm,
Sweden (ticker: NUE). Västra Hamnen Corporate Finance AB acts as Certified
Adviser to Nuevolution AB (publ). More information about Nuevolution can be
found on: www.nuevolution.com
hs@nuevolution.com

+45 2289 9209